Pro-Dex, Inc. Announces Fiscal 2021 Fourth Quarter and Full-Year Results

IRVINE, CA / ACCESSWIRE / August 26, 2021 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2021 fourth quarter and full-year ended June 30, 2021.

Quarter Ended June 30, 2021

Net sales for the three months ended June 30, 2021 decreased $1.7 million, or15%, to $9.4 million from $11.1 million for the three months ended June 30, 2020, due primarily to decreased medical device sales. This is due to two product launches in the prior fiscal year which had high initial sales volumes, which is typical, as our customers generally order in higher volumes in the beginning of a product introduction. Also, six to twelve months following launch our customers typically begin reordering these products on a quarterly basis and these orders continue to help facilitate our year-over-year growth. Gross profitfor the three monthsended June 30, 2021 decreased $1.2 million, or 27%, to $3.1 million from $4.3 million for the same period in 2020. The decrease in gross margin is due to a decline in 4th quarter sales of the two aforementioned product launches, as well as price concessions to our largest customer, coupled with under-absorption of our fixed costs resulting, in part, from lower sales volumes.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended June 30, 2021 increased 21% to $2.5 million from $2.1 million in the prior year’s corresponding quarter, due primarily to increased expenditures of $385,000 in research and development costs to support our continued efforts to further grow our business.

Net income for the quarter ended June 30, 2021 decreased by $1.7 million to $0.9 million, or $0.22 per diluted share, compared to $2.5 million, or $0.64 per diluted share, in the corresponding quarter in 2020.

Year Ended June 30, 2021

Net sales for the fiscal year ended June 30, 2021 increased $3.2 million, or 9%, to $38.0 million from $34.8 million for the fiscal year ended June 30, 2020, due primarily to increases in medical device revenues. Specifically, we generated an increase in sales of $4.8 million in fiscal 2021 over fiscal 2020 due to the new thoracic driver we launched to our second largest customer in the prior fiscal year, much of which represented the fulfillment of their initial launch orders.

Grossprofit for the fiscal yearended June 30, 2021 increased $0.4 million, or 3%, to $13.6 million compared to $13.1 million for fiscal 2020, due to increased revenues.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the fiscal year ended June 30, 2021 increased 49% to $9.1 million from $6.1 million in the prior fiscal year. Of the total increase in operating expenses, $887,000 relates to an increase in general and administrative expenses primarily due to increased non-cash stock compensation expense in the amount of $615,000 as well as $267,000 in expenses related to our newly acquired commercial building. Our $2.1 million increase in research and development costs from fiscal 2020 to fiscal 2021 reflects our continued investment in new product development as well as our commitment to continuous improvement of our existing products.

Net income for the fiscal year ended June 30, 2021 was $4.5 million, or $1.13 per diluted share, compared to $6.1 million, or $1.50 per diluted share, for fiscal 2020.

Although we have released our earnings prior to our Annual Report on Form 10-K with the Securities and Exchange Commission, we are able to do this because we are a non-accelerated filer and as a result have more time to do so at fiscal year-end. During our quarterly reporting periods, we anticipate that our earnings releases will continue to be released at the same time as our Form 10-Q’s are filed with the Securities and Exchange Commission. We anticipate filing our Form 10-K with the Securities and Exchange Commission on September 9, 2021.

Guidance

Pro-Dex typically does not provide sales, earnings, or other guidance, and while the COVID-19 pandemic did not materially adversely affect our financial results in our fiscal year ended June 30, 2021, we did experience under-absorbed manufacturing costs, due in part from compensated absences related to COVID-19, a portion of which we expect to recover from amended payroll tax returns, as prescribed by the Families First Coronavirus Response Act. Additionally, during calendar 2021, we began to see some challenges in our supply chain in the form of delayed shipments, longer lead times, and surcharges, much of which our suppliers indicate have been caused by the pandemic. If any of these conditions persist or are exacerbated in the future, we could be negatively impacted. We have and continue to implement plans and processes to mitigate these challenges that many manufacturers similarly face. Our prospects remain positive with additional capacity forthcoming to allow for continued sales growth through our aggressive product development efforts.

CEO Comments

“We are very pleased with our continued year-over-year sales growth, as well as the progress we have made in readying our new building for move-in.” said the Company’s President and Chief Executive Officer Richard L. (“Rick”) Van Kirk. “While we are unable to predict the total impact of the COVID-19 pandemic, we remain vigilant in our efforts to provide a safe workplace for our employees, excellent service to our customers, and continue to focus on strategic investments in plant and equipment and product development efforts to continue to grow our business. With our new building and additional capacity coming online this year, combined with our focus on new business development and technology, we are excited about fulfilling the potential of the new building and growing our business significantly for years to come.”

R&D Projects

The amount spent on projects under development is summarized below (in thousands):


 
 Years Ended June 30,       

 
 2021  2020  ExpectedMarket Launch(1)  Estimated AnnualRevenue 

 
 Dollars in thousands  
 
  
 
 
Total Research and Development costs: 4,384  2,315  
 
  
 
 

 
         
 
  
 
 
Products in development:         
 
  
 
 
ENT Shaver  829   475   Q4 2021  1,000 
CMF Driver  826   194   (2) 1,000 
Vital Ventilator  191      Q1 2022  1,500 
Sustaining & Other  2,538   1,646         
Total 4,384  2,315         
  1. Represents the calendar quarter of expected market launch.
  2. The CMF Driver was completed in the third quarter of fiscal 2021 and shipped to our existing largest customer under a distribution agreement we executed in the first quarter of fiscal 2021. We generated revenue of $220,000 related to these initial shipments during the third quarter ended March 31, 2021. This project is now complete and future engineering expenses related to this project will be included in sustaining and other engineering expenses.

As we introduce new products into the market, we expect to see an increase in sustaining and other engineering expenses. Typical examples of sustaining engineering activities include, but are not limited to, end-of life component replacement, especially in electronic components found in our PCB assemblies, analysis of customer complaint data to improve process and design, replacement and enhancement of tooling and fixtures used in our machine shop, assembly operations and inspection areas to improve efficiency and through-put. Additionally, these costs include development projects that may be in their infancy and may or may not result in a full-fledged product development effort.

About Pro-Dex, Inc.:

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex also sells rotary air motors. Pro-Dex’s products are found in hospitals and medical engineering labs around the world. For more information, visit the Company’s website at www.pro-dex.com.

Statements herein concerning the Company’s plans, growth and strategies may include “forward-looking statements” within the context of the federal securities laws. Statements regarding the Company’s future events, developments and future performance (including, but not limited to, the potential future impact of the COVID-19 pandemic, the timing of expected market launches, and the estimated annual revenue from new product launches) as well as management’s expectations, beliefs, plans, estimates, or projections relating to the future are forward-looking statements within the meaning of these laws. The Company’s actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company’s filings with the Securities and Exchange Commission.

PRO-DEX, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)


 
 June 30, 

 
 2021  2020 
ASSETS 
 
  
 
 
Current assets: 
 
  
 
 
Cash and cash equivalents $3,721  $6,421 
Investments  1,295   2,560 
Accounts receivable, net of allowance for doubtful accounts of $2 and $6 at June 30, 2021 and 2020, respectively  10,933   5,155 
Deferred costs  193   155 
Inventory  8,437   8,238 
Prepaid expenses and other current assets  434   145 
Total current assets  25,013   22,674 
Land and building, net  6,437    
Equipment and improvements, net  3,845   2,686 
Right of use asset, net  2,605   2,943 
Intangibles, net  186   162 
Deferred income taxes, net  463   259 
Investments  1,704   2,360 
Other assets  67   42 
Total assets $40,320  $31,126 

 
        
LIABILITIES AND SHAREHOLDERS’ EQUITY        
Current liabilities:        
Accounts payable $2,288  $1,965 
Accrued liabilities  2,198   2,411 
Deferred revenue  150   200 
Notes payable  1,236   651 
Total current liabilities.  5,872   5,227 
Non-current liabilities:        
Lease liability, net of current portion  2,432   2,750 
Income taxes payable  397   804 
Notes payable, net of current portion  11,535   3,283 
Total non-current liabilities  14,364   6,837 
Total liabilities  20,236   12,064 

 
        
Commitments and Contingencies:        

 
        
Shareholders’ equity:        
Common stock, no par value, 50,000,000 shares authorized; 3,645,660 and 3,811,137 shares issued and outstanding at June 30, 2021 and 2020, respectively  7,953   12,752 
Accumulated other comprehensive loss  (215)  (1,586)
Retained earnings  12,346   7,896 
Total shareholders’ equity  20,084   19,062 
Total liabilities and shareholders’ equity $40,320  $31,126 


PRO-DEX, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)


 
 Three Months Ended
June 30,(Unaudited)
  Years Ended
June 30,
 

 
 2021  2020  2021  2020 

 
 
 
  
 
  
 
  
 
 
Net sales. $9,435  $11,125  $38,029  $34,834 
Cost of sales  6,316   6,837   24,454   21,692 
Gross profit  3,119   4,288   13,575   13,142 

 
                
Operating (income) expenses:Selling expenses  175   138   590   577 
General and administrative expenses  1,154   1,137   4,076   3,189 
Gain from disposal of equipment     (5)     (5)
Research and development costs  1,200   815   4,384   2,315 
Total operating expenses  2,529   2,085   9,050   6,076 

 
                
Operating profit  590   2,203   4,525   7,066 
Interest expense  (121)  (56)  (352)  (236)
Other income     935      952 
Gain on sale of investments  533   25   1,327   25 
Interest and dividend income  23   35   126   95 

 
                
Income before income taxes  1,025   3,142   5,626   7,902 
Income tax expense  173   596   1,176   1,790 
Net income $852  $2,546  $4,450  $6,112 

 
                
Basic & Diluted income per share:                
Basic net income per share $0.23  $0.67  $1.17  $1.56 

 
                
Diluted net income per share $0.22  $0.64  $1.13  $1.50 

 
                
Weighted average shares outstanding:                
Basic  3,656,052   3,812,145   3,796,516   3,910,940 
Diluted  3,796,056   3,979,944   3,936,194   4,078,087 


PRO-DEX, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)


 
 Years Ended June 30, 

 
 2021  2020 
CASH FLOWS FROM OPERATING ACTIVITIES: 
 
  
 
 
Net income $4,450  $6,112 
Adjustments to reconcile net income to net cash provided by (used in) operating activities:        
Depreciation and amortization  686   573 
Gain on collection of note receivable     (952)
Gain on sale of investments  (1,327)  (25)
Non-cash lease expense  26   41 
Gain on sale or disposal of equipment     (5)
Amortization of loan fees  49   9 
Share-based compensation  901   286 
Deferred income taxes  (181)  (22)
Bad debt expense  5   6 
Changes in operating assets and liabilities:        
Accounts receivable  (5,783)  (1,061)
Deferred costs  (38)  275 
Inventory  (199)  (1,999)
Prepaid expenses and other assets  (314)  476 
Accounts payable, accrued expenses and deferred rent  105   604 
Deferred revenue  (50)  (15)
Income taxes payable  (408)  642 
Net cash provided by (used in) operating activities  (2,078)  4,945 

 
        
CASH FLOWS FROM INVESTING ACTIVITIES:        
Purchases of equipment and leasehold improvements  (1,769)  (519)
Purchase of land and building  (6,499)   
Proceeds from dividend reclassified as return of principal     15 
Proceeds from sale of equipment     5 
Proceeds from collection of notes receivable     952 
Proceeds from sale of investments  4,596   128 
Increase in intangibles  (38)  (46)
Purchase of investments     (2,822)
Net cash used in investing activities  (3,710)  (2,287)

 
        
CASH FLOWS FROM FINANCING ACTIVITIES:        
Principal payments on notes payable  (352)  (630)
Borrowing from Minnesota Bank & Trust, net of loan origination fees  9,139    
Repurchases of common stock  (5,537)  (3,388)
Payments of employee taxes on net issuance of common stock  (259)   
Proceeds from exercise of stock options and ESPP contributions  97   39 
Net cash provided by (used in) financing activities  3,088   (3,979)

 
        
Net decrease in cash and cash equivalents  (2,700)  (1,321)
Cash and cash equivalents, beginning of year  6,421   7,742 
Cash and cash equivalents, end of year. $3,721  $6,421 


SOURCE: Pro-dex, Inc.

View source version on accesswire.com: 
https://www.accesswire.com/661343/Pro-Dex-Inc-Announces-Fiscal-2021-Fourth-Quarter-and-Full-Year-Results

About The Wall Street Analyzer 1630 Articles
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.

Be the first to comment

Leave a Reply